Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
A Phase IIA, open-label, multicenter, active-controlled, parallel-group clinical trial
designed to evaluate the safety and efficacy of two doses of Bucillamine compared with
low-dose Colchicine in the treatment of patients with acute gout flare.